Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

Similarly, 10 μM CHCA increased human PMM2 enzymatic activity by 40%, which was marginally statistically significant because of the variance ( P =0.0436), as shown in Fig. 5 B.

also in 1,110 other papers